Royal Bank Of Canada Reiterates “Hold” Rating for Endologix, Inc. (ELGX)
Endologix, Inc. (NASDAQ:ELGX)‘s stock had its “hold” rating reaffirmed by Royal Bank Of Canada in a research report issued on Tuesday. They currently have a $5.00 target price on the medical instruments supplier’s stock. Royal Bank Of Canada’s target price points to a potential downside of 11.50% from the stock’s current price.
A number of other analysts have also recently commented on ELGX. Canaccord Genuity reissued a “hold” rating and issued a $5.00 price target on shares of Endologix in a research report on Wednesday, September 27th. Oppenheimer Holdings, Inc. set a $5.00 price target on Endologix and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Stifel Nicolaus set a $6.00 price target on Endologix and gave the stock a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research cut Endologix from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, BidaskClub cut Endologix from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. The stock has an average rating of “Hold” and an average target price of $6.28.
Endologix (NASDAQ ELGX) traded down 0.088% on Tuesday, hitting $5.645. The stock had a trading volume of 261,447 shares. The company’s market cap is $470.98 million. The stock has a 50 day moving average price of $4.45 and a 200 day moving average price of $5.35. Endologix has a 1-year low of $4.08 and a 1-year high of $13.24.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $47.58 million. During the same period in the previous year, the firm posted ($0.20) EPS. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. On average, equities research analysts expect that Endologix will post ($0.62) EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its position in Endologix by 7.1% in the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock valued at $361,000 after acquiring an additional 3,290 shares in the last quarter. Camber Capital Management LLC lifted its position in Endologix by 65.1% in the 1st quarter. Camber Capital Management LLC now owns 6,000,000 shares of the medical instruments supplier’s stock valued at $43,440,000 after acquiring an additional 2,365,000 shares in the last quarter. Iguana Healthcare Management LLC bought a new position in Endologix in the 1st quarter valued at approximately $1,086,000. Endurant Capital Management LP bought a new position in Endologix in the 1st quarter valued at approximately $2,425,000. Finally, MARSHALL WACE ASIA Ltd bought a new position in Endologix in the 1st quarter valued at approximately $323,000.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.